Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor

Inclusion Criteria: * Inclusion criteria: 1. Age ≥18 years old, male or female; 2. Subjects had squamous cell carcinoma of the head and neck confirmed by histrohistology or cytology; 3. CLINICAL STAGE III OR IV WITHOUT DISTANT METASTASES (AJCC 8th) 4. Patients who have not previously received initial treatment with chemotherapy or radiation; 5. KPS acuity 70; 6. Normal bone marrow reserve function and normal liver and kidney function; 7. Expected survival time ≥3 months; 8. Subjects of child-bearing age must agree to use effective contraceptive measures during the study period; The serum or urine pregnancy test must be negative for women of childbearing age 72 hours before the start of chemotherapy; 9. Subjects have good compliance, can carry out treatment and follow-up, and voluntarily abide by the regulations of this study; 10. Subjects voluntarily sign the informed consent. Exclusion Criteria: * Exclusion criteria: 1. Patients with distant metastasis; 2. The presence of uncontrolled serious medical diseases, such as combined with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.; 3. The presence of dementia, altered mental status or any mental illness that would prevent understanding or giving informed consent or filling out questionnaires; 4. Subjects with grade ≥2 peripheral neuropathy according to CTCAE V5.0; 5. A history of allergy or hypersensitivity to any therapeutic ingredient; 6. Suffered from malignant tumors other than squamous cell carcinoma of the head and neck in the past 5 years, except adequately treated basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery; 7. Abnormal results of physical and laboratory tests: A) Hematologic abnormalities are defined as: I) Absolute count of neutrophils (ANC) : \< 1.5×109 / L; Ii) Platelet (PLT) count: \< 100×109/L; Iii) Hemoglobin (Hb) level \< 90g/L; B) Abnormal liver function is defined as: I) Total bilirubin (TBIL) level: 1.5 times of the upper limit of normal value of \> (ULN); Ii) AST and ALT levels of \>ULN were 2.5 times, and BBB\>N was 5 times if liver metastasis was present; C) Definition of abnormal renal function: 1.5 times of serum creatinine \> ULN, or the calculated creatinine clearance rate \< 50ml/min; 8. Patients who need to be treated with other anti-tumor drugs; 9. Has received any other investigational drug therapy or participated in another interventional clinical trial within 30 days prior to screening; 10. The researcher considers it unsuitable for inclusion; 11. Pregnant or lactating women.